{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-032777","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-07-10T12:00:24+00:00","discovered_at":"2026-07-10T12:05:00.324538+00:00","generated_at":"2026-07-10T12:05:21.244215+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MIRA Pharmaceuticals reports positive preclinical results for MIRA-55 oral formulation for chronic pain","bullets":["Selected lead oral formulation of MIRA-55 with favorable oral bioavailability and sustained systemic exposure.","Formulation demonstrated reproducible distribution into brain and liver tissue after oral administration.","Prior studies showed oral MIRA-55 normalized pain and reduced inflammation, outperforming injected morphine.","MIRA-55 exhibited anxiolytic activity and no THC-like CNS effects; interacts with cannabinoid system distinct from THC.","Company plans further preclinical evaluation of tissue exposure, pharmacodynamic activity, and therapeutic efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-032777","json":"https://secwatch.observer/filing/0001493152-26-032777.json","markdown":"https://secwatch.observer/filing/0001493152-26-032777.md","text":"https://secwatch.observer/filing/0001493152-26-032777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226032777/0001493152-26-032777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226032777/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-10T12:05:21.244215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}